Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
On behalf of my coauthors, I thank Dr Hersey for his insightful analysis of our manuscript describing pyrexia characteristics in patients treated with dabrafenib plus trametinib, a topic of critical importance given that pyrexia is the most common adverse event associated with this treatment combination. The goal of our manuscript was to describe pyrexia incidence and management patterns among patients who received dabrafenib plus trametinib in clinical trials. Notably, the 1076 patients included in our analysis encompassed those with advanced non-small cell lung cancer (n  = 82), stage III resectable melanoma (n...
Source: European Journal of Cancer - December 4, 2021 Category: Cancer & Oncology Authors: Dirk Schadendorf Tags: Author ’s reply Source Type: research

Precision dosing in children; no small matter
Most paediatricians are very apt in arithmetic. This competency has usually been developed through years of exercise in prescribing drugs for children. Day or nighttime, treating a preterm neonate or an obese adolescent, using drugs with a small or broad therapeutic window, and even in emergency settings, paediatricians need to calculate and use the correct dosages. The importance of correct dosing is widely recognised by anyone who has ever attended a pharmacology course; the delicate balance between efficacy and toxicity of a drug is pre-eminently determined by the dosage. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 4, 2021 Category: Cancer & Oncology Authors: L.M. Hanff Tags: Editorial Source Type: research

Disease-specific outcomes after chimeric antigen receptor T-cell therapy
We compared outcomes of patients with B-cell malignancies treated in clinical trials with the same CD19 chimeric antigen receptor (CAR) T-cells across different indications, including B-cell acute lymphoblastic leukaemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). We found that for a given CAR T-cell, efficacy and toxicity varied depending on the disease. Overall, we found a low rate of primary resistance in FL, MCL and B-ALL compared with DLBCL. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2021 Category: Cancer & Oncology Authors: Jean Lemoine, Samuel Vic, Roch Houot Tags: Current Perspective Source Type: research

Localised rhabdomyosarcoma in infants ( < 12 months) and young children (12 –36 months of age) treated on the EpSSG RMS 2005 study
Infants ( (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2021 Category: Cancer & Oncology Authors: Olga Slater, Jennifer E. Gains, Anna M. Kelsey, Federica De Corti, Ilaria Zanetti, Beatrice Coppadoro, Mette Jorgensen, Soledad Gallego, Daniel H. Orbach, Heidi Glosli, Maja Cesen, Mark N. Gaze, Naima Smeulders, Andrea Ferrari, Meriel Jenney, Veronique Mi Tags: Original Research Source Type: research

Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance
Cancer in neonates and infants is a rare but challenging entity. Treatment is complicated by marked physiological changes during the first year of life, excess rates of toxicity, mortality, and late effects. Dose optimisation of chemotherapeutics may be an important step to improving outcomes. Body size –based dosing is used for most anticancer drugs used in infants. However, dose regimens are generally not evidence based, and dosing strategies are frequently inconsistent between tumour types and treatment protocols. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2021 Category: Cancer & Oncology Authors: A. Laura Nijstad, Shelby Barnett, Arief Lalmohamed, Inez M. B érénos, Elizabeth Parke, Vickyanne Carruthers, Deborah A. Tweddle, Jordon Kong, C. Michel Zwaan, Alwin D.R. Huitema, Gareth J. Veal Tags: Review Source Type: research

Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has revolutionised the treatment for multiple lymphoproliferative disorders and chronic graft versus host disease [1]. It is explored in the treatment of more and more cancer types and presents anti-skin cancer activity as inhibiting the proliferation of skin cancer cells and inducing apoptosis and autophagy in basic research [2]. However, in a phase II single-arm clinical trial which further assessed the ibrutinib effect on melanoma cells, no antitumour responses were seen [3]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2021 Category: Cancer & Oncology Authors: Ximu Sun, Zhuo Ma, Qixiang Guo, Zhixia Zhao, Lihong Liu Tags: Letter to the Editor Source Type: research

Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials
Immune checkpoint inhibitors (ICIs) are now a cornerstone of advanced non-small cell lung cancer (NSCLC) treatment. However, heterogeneity in ICI benefit is significant, and it is increasingly apparent that resistance is likely multifactorial. As cigarette smoking is associated with increased tumour mutation burden (TMB) [1,2], it is possible that ‘never smokers’ could obtain less ICI benefit. Recent study-level meta-analyses report that never smokers may obtain less effect from ICIs than previous/current smokers [3,4], while small cohort studies report prognosis may be poorer in never smokers compared to previ...
Source: European Journal of Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Ashley M. Hopkins, Ahmad Y. Abuhelwa, Ross A. McKinnon, Jessica M. Logan, Ganessan Kichenadasse, Andrew Rowland, Michael J. Sorich Tags: Letter to the Editor Source Type: research

Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non –small cell lung cancer
An increasing number of advanced non –small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients wi th NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Hidenori Mizugaki, Satoshi Oizumi, Yuka Fujita, Toshiyuki Harada, Yoshiro Nakahara, Taichi Takashina, Ryo Ko, Kageaki Watanabe, Takamasa Hotta, Hiroyuki Minemura, Sho Saeki, Hajime Asahina, Keiichi Nakamura, Hiromi Nakamura, Fumie Hosoda, Shigehiro Yagish Tags: Original Research Source Type: research

Impact of reducing excess body weight and physical inactivity on cancer incidence in Germany from 2020 to 2050 —a simulation model
Excess body weight and physical inactivity are key cancer risk factors contributing substantially to the cancer burden in Germany. We aimed to estimate the numbers and proportions of future cancer cases prevented under different scenarios of reducing the prevalence of excess body weight and physical inactivity in Germany. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Thomas Gredner, Tobias Niedermaier, Karen Steindorf, Hermann Brenner, Ute Mons Tags: Original Research Source Type: research

Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma
Immune checkpoint inhibitors (ICIs) blocking engagement with the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) or the programmed death 1 (PD-1) receptors have emerged to dramatically improve the treatment outcome of various advanced cancer types. In melanoma, the combination of nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) has demonstrated significantly improved long-term survival [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Sarah Qaiyumi, Wolfram Klapper, Axel Hauschild, Michael Weichenthal Tags: Letter to the Editor Source Type: research

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Innovations in treatments, imaging and molecular characterisation have improved outcomes for people with advanced prostate cancer; however, many aspects of clinical management are devoid of high-level evidence. At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, many of these topics were addressed, and consensus was not always reached. The results from clinical trials will most reliably plus the gaps. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Ursula M. Vogl, Tomasz M. Beer, Ian D. Davis, Neal D. Shore, Christopher J. Sweeney, Piet Ost, Gerhardt Attard, Alberto Bossi, Johann de Bono, Charles G. Drake, Eleni Efstathiou, Stefano Fanti, Karim Fizazi, Susan Halabi, Nicolas James, Nicolas Mottet, An Tags: Review Source Type: research

Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer
Mesenchyme homeobox-2 (MEOX2)-mediated regulation of glioma-associated oncogene-1 (GLI1) has been associated with poor overall survival, conferring chemoresistance in lung cancer. However, the role of MEOX2/GLI1 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)-based therapy remains unexplored in human lung cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Irlanda Peralta-Arrieta, Octavio A. Trejo-Villegas, Leonel Armas-L ópez, Hugo A. Ceja-Rangel, María del Carmen Ordóñez-Luna, Priscila Pineda-Villegas, Marco A. González-López, Blanca Ortiz-Quintero, Criselda Mendoza-Milla, Zyanya L. Zatarain-Barrón Tags: Original Research Source Type: research

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation
Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BRCA1/2 mutations in 3 phases III trials. The single-arm phase II RUBY trial included 42 patients, 40 of whom received at least one dose of rucaparib. RUBY study assessed the efficacy of rucaparib in HER2-mBC with either high genomic loss of heterozygosity (LOH) score or non-germline BRCA1/2 mutation. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gon çalves, Monica Arnedos, Marie-Paule Sablin, Pascal Jézéquel, Marta Jimenez, Nathalie Droin, Ivan Bièche, Céline Callens, Andrea Loehr, Cécile Vicier, Catherine Guerin, Thomas Fi Tags: Clinical Trial Source Type: research

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Andrew DJ. Pearson, Claudia Rossig, Crystal Mackall, Nirali N. Shah, Andre Baruchel, Gregory Reaman, Rosanna Ricafort, Delphine Heenen, Abraham Bassan, Michael Berntgen, Nick Bird, Eric Bleickardt, Najat Bouchkouj, Peter Bross, Carrie Brownstein, Sarah Be Tags: Review Source Type: research

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre  prospective study
We would like to thank the authors Sekkate et  al. for their letter describing findings from a single-centre prospective study at Foch Hospital in France. Their aim was to evaluate anti-SARS-CoV-2 antibody titers in patients with solid tumours (excluding lung cancers) who had received two doses of the BNT162b2 vaccine and to assess the corre lation between these titers and lymphocyte count. Their study included 237 patients who had received two doses of the BNT162b2 vaccine. Blood samples for anti-spike antibodies and lymphocyte determinations were taken 3–4 months following vaccination. (Source: ...
Source: European Journal of Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Einat Shacham-Shmueli, Amit Itay, Ofer Margalit, Raanan Berger, Sharon Halperin, Menucha Jurkowicz, Einav G. Levin, Itzchak Levy, Liraz Olmer, Gili Regev-Yochay, Yaniv Lustig, Galia Rahav Tags: Letter to the Editor Source Type: research

Monitoring patients at risk for melanoma: May convolutional neural networks replace the strategy of sequential digital dermoscopy?
Sequential digital dermoscopy (SDD) is applied for early melanoma detection by uncovering dynamic changes of monitored lesions. Convolutional neural networks (CNN) are capable of high diagnostic accuracies similar to trained dermatologists. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Julia K. Winkler, Philipp Tschandl, Ferdinand Toberer, Katharina Sies, Christine Fink, Alexander Enk, Harald Kittler, Holger A. Haenssle Tags: Original Research Source Type: research

Neoadjuvant therapy or upfront surgery for resectable  and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials
Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y.V. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H.J. van Eijck, Bas Groot Koerkamp, Dutch Pancreatic Cancer Group Tags: Original Research Source Type: research

Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal CANCERS in The Netherlands
This study aimed to assess the impact of the COVID-19 pandemic on incidence and stage distribution of CRCs in the Netherlands, by monitoring CRC diagnoses and stage distribution in the months before, during and after the first COVID-19 wave. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Esther Toes-Zoutendijk, Geraldine Vink, Iris D. Nagtegaal, Manon C.W. Spaander, Evelien Dekker, Monique E. van Leerdam, Sabine Siesling, Iris Lansdorp-Vogelaar, Marloes A.G. Elferink Tags: Current Perspective Source Type: research

Therapeutic vaccines for breast cancer: Has the time finally come?
The ability to exploit the immune system as a weapon against cancer has revolutionised the treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs). However, ICIs demonstrated a modest benefit in treating breast cancer (BC), with the exception of certain subsets of triple-negative BCs. An immune-suppressive tumour microenvironment (TME), typically present in BC, is an important factor in the poor response to immunotherapy.After almost two decades of poor clinical trial results, cancer vaccines (CVs), an active immunotherapy, have come back in the spotlight because of some technological advanceme...
Source: European Journal of Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Chiara Corti, Pier P.M.B. Giachetti, Alexander M.M. Eggermont, Suzette Delaloge, Giuseppe Curigliano Tags: Review Source Type: research

Overall survival for oncology drugs approved for genomic indications
Drug approvals for genome-informed indications have been increasing in recent years, but it is unknown how many of them have demonstrated an improvement in overall survival (OS). We assessed the frequency of approved genome-informed drugs demonstrating improvements in OS and progression-free survival (PFS)  and whether the frequencies differed by cancer type. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Alyson Haslam, Myung Sun Kim, Vinay Prasad Tags: Original Research Source Type: research

Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review
Over the past decade, the development of molecular high-throughput methods (omics) increased rapidly and provided new insights for cancer research. In parallel, deep learning approaches revealed the enormous potential for medical image analysis, especially in digital pathology. Combining image and omics data with deep learning tools may enable the discovery of new cancer biomarkers and a more precise prediction of patient prognosis. This systematic review addresses different multimodal fusion methods of convolutional neural network-based image analyses with omics data, focussing on the impact of data combination on the cla...
Source: European Journal of Cancer - November 19, 2021 Category: Cancer & Oncology Authors: Lucas Schneider, Sara Laiouar-Pedari, Sara Kuntz, Eva Krieghoff-Henning, Achim Hekler, Jakob N. Kather, Timo Gaiser, Stefan Fr öhling, Titus J. Brinker Tags: Review Source Type: research

The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study
This study aims to investigate the association between cisplatin pharmacokinetics and SMM in patients with HNSCC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 19, 2021 Category: Cancer & Oncology Authors: Najiba Chargi, Laura Molenaar-Kuijsten, Laura F.J. Huiskamp, Lot A. Devriese, Remco de Bree, Alwin D.R. Huitema Tags: Original Research Source Type: research

Anti –programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
This study investigated the tolerability and efficacy of anti –programmed death ligand 1 (PD (L)1) immunotherapies in patients with pre-existing SSc. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 19, 2021 Category: Cancer & Oncology Authors: Marion Panhaleux, Olivier Espitia, Benjamin Terrier, Guillaume Manson, Alexandre Maria, S ébastien Humbert, Benoît Godbert, Julie Perrin, Aurélie Achille, Jennifer Arrondeau, Marie Kostine, Vincent Fallet, Grégory Pugnet, Benjamin Chaigne, Stéphane C Tags: Original Research Source Type: research

Nivolumab plus docetaxel in patients with chemotherapy-na ïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC). (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Karim Fizazi, Pablo Gonz ález Mella, Daniel Castellano, Jose N. Minatta, Arash Rezazadeh Kalebasty, David Shaffer, Juan C. Vázquez Limón, Héctor M. Sánchez López, Andrew J. Armstrong, Lisa Horvath, Diogo A. Bastos, Neha P. Amin, Jia Li, Keziban Unsa Tags: Original Research Source Type: research

Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapy —A matter of concern
Neoadjuvant treatment (nTx) for rectal cancer is commonly reserved for UICC stages II/III. Patients with stage I tumours (T1-2N0M0) are not candidates for  nTx. The accuracy of treatment allocation depends on the precision of clinical staging, which is liable to understaging and overstaging. The study aimed at exploring changes in the proportion of stage pI patients with the introduction of nTx over a 26-year period. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 17, 2021 Category: Cancer & Oncology Authors: Sigmar Stelzner, Erik Puffer, Joerg Zimmer, Dorothea Bleyl, Thomas Kittner, Matthias Kuhn, Christiane Jakob, Helmut Witzigmann, Soeren T. Mees Tags: Original Research Source Type: research

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety,  and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type melanoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 17, 2021 Category: Cancer & Oncology Authors: Michele Maio, Matteo S. Carlino, Anthony M. Joshua, Elaine McWhirter, Antoni Ribas, Paolo A. Ascierto, Wilson H. Miller, Marcus O. Butler, Pier Francesco Ferrucci, Robert R. Zielinski, Michele Del Vecchio, Eduard Gasal, Razi Ghori, Scott J. Diede, Elizabe Tags: Original Research Source Type: research

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) in triple-negative breast cancer [TNBC]) in high-risk early breast cancer (BC). Here, we report time-to-event secondary end-points. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 17, 2021 Category: Cancer & Oncology Authors: Andreas Schneeweiss, Laura L. Michel, Volker M öbus, Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl-Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch, Jens-Uwe Blohmer, Peter A. Fasching, Christine S Tags: Original Research Source Type: research

The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples
Paediatric tumours are often characterised by the presence of recurrent DNA copy number alterations (CNAs). These DNA copy number profiles, obtained from a tissue biopsy, can aid in the correct prognostic classification and therapeutic stratification of several paediatric cancer entities (e.g. MYCN amplification in neuroblastoma) and are part of the routine diagnostic practice. Liquid biopsies (LQBs) offer a potentially safer alternative for such invasive tumour tissue biopsies and can provide deeper insight into tumour heterogeneity. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 16, 2021 Category: Cancer & Oncology Authors: Ruben Van Paemel, Charlotte Vandeputte, Lennart Raman, Jolien Van Thorre, Leen Willems, Jo Van Dorpe, Mala ïka Van Der Linden, Jilke De Wilde, Andries De Koker, Björn Menten, Christine Devalck, Ales Vicha, Marek Grega, Gudrun Schleiermacher, Yasmine Idd Tags: Original Research Source Type: research

A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients
While genome-wide association studies (GWAS) have identified germline variants influencing the risk of developing colorectal cancer (CRC), there has been limited examination of the possible role of inherited variation as a determinant of patient outcome. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 15, 2021 Category: Cancer & Oncology Authors: Christopher Wills, Yazhou He, Matthew G. Summers, Yi Lin, Amanda I. Phipps, Katie Watts, Philip J. Law, Nada A. Al-Tassan, Timothy S. Maughan, Richard Kaplan, Richard S. Houlston, Ulrike Peters, Polly A. Newcomb, Andrew T. Chan, Daniel D. Buchanan, Steve Tags: Original Research Source Type: research

Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 13, 2021 Category: Cancer & Oncology Authors: Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, David Penson, Fred Saad, Eleni Efstathiou, Katarzyna Madziarska, Joyce Steinberg, Jennifer Sugg, Xun Lin, Qi Shen, Cora N. Sternberg Tags: Original Research Source Type: research

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 13, 2021 Category: Cancer & Oncology Authors: J. Stutterheim, P. de Lorenzo, I.M. van der Sluin, J. Alten, P. Ancliffe, A. Attarbaschi, L. Aversa, J.M. Boer, A. Biondi, B. Brethon, P. Diaz, G. Cazzaniga, G. Escherich, A. Ferster, R.S. Kotecha, B. Lausen, Alex WK. Leung, F. Locatelli, L. Silverman, J. Tags: Original Research Source Type: research

TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients
Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC study aimed at exploring the combination of paclitaxel and LY2780301 in this population. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Keyvan Rezai, Magali Provansal, Jos é Adélaïde, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Cornel Popovici, Emmanuelle Charafe-Jauffret, Max Chaf Tags: Original Research Source Type: research

Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations
Brain metastases present a significant complication in lung cancer with an unmet therapeutic need. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Erik Vassella, Elham Kashani, Philipp Zens, Alexandra K ündig, Christian Fung, Amina Scherz, Evelyn Herrmann, Ekin Ermis, Ralph A. Schmid, Sabina Berezowska Tags: Original Research Source Type: research

Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy
We congratulate Vrieling C et  al. [1] on their publication, which investigated the impact of ipsilateral breast tumour recurrence (IBTR) on oncological outcomes after breast conservative treatment in early breast cancer. The study population was derived from two European Organisation for Research and Treatment of Cancer random ised trials (22881-10882 ‘boost-no boost’ and 22922-10925 ‘IM-MS’). Among the 8367 patients analysed in the whole cohort, 726 experienced an isolated IBTR. The authors showed that patients who presented an IBTR had a higher risk of developing distant metastases, whe...
Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Jean-Michel Hannoun-Levi, Cristina Gutierrez, Csaba Polgar, Vratislav Strnad, the BCWG of the GEC-ESTRO Tags: Letter to the Editor Source Type: research

A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant chemotherapy, including gemcitabine, nab-paclitaxel  and S-1 (GAS), for patients with BRPC-A. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 12, 2021 Category: Cancer & Oncology Authors: Naru Kondo, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Tatsuaki Sumiyoshi, Kenjiro Okada, Shingo Seo, Hiroyuki Otsuka, Yoshiaki Murakami, Shinya Takahashi Tags: Clinical Trial Source Type: research

Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort
Recommendations for managing patients with nasopharyngeal carcinoma (NPC)  in non-endemic areas are largely derived from studies conducted in endemic areas. We analysed the impact of treatment approaches on survival in non-endemic areas. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 11, 2021 Category: Cancer & Oncology Authors: Paolo Bossi, Annalisa Trama, Alice Bernasconi, Salvatore Grisanti, Issa Mohamad, Isabel L. Galiana, Enis Ozyar, Pierfrancesco Franco, Stefania Vecchio, Pierluigi Bonomo, Beatriz C. Cirauqui, Mustafa El-Sherify, Stefano Ursino, Athanassios Argiris, Jonatha Tags: Original Research Source Type: research

High-resolution three-dimensional imaging for precise staging in melanoma
Many cancer guidelines include sentinel lymph node (SLN) staging to identify microscopic metastatic disease. Current SLN analysis of melanoma patients is effective but has the substantial drawback that only a small representative portion of the node is sampled, whereas most of the tissue is discarded. This might explain the high clinical false-negative rate of current SLN diagnosis in melanoma. Furthermore, the quantitative assessment of metastatic load and microanatomical localisation might yield prognosis with higher precision. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 10, 2021 Category: Cancer & Oncology Authors: Simon F. Merz, Philipp Jansen, Ricarda Ulankiewicz, Lea Bornemann, Tobias Schimming, Klaus Griewank, Z ülal Cibir, Andreas Kraus, Ingo Stoffels, Timo Aspelmeier, Sven Brandau, Dirk Schadendorf, Eva Hadaschik, Gernot Ebel, Matthias Gunzer, Joachim Klode Tags: Original Research Source Type: research

First-line osimertinib in patients with epidermal growth factor receptor –mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation –positive advanced non–small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 8, 2021 Category: Cancer & Oncology Authors: Margarita Majem, Ivanna Sullivan, Santiago Viteri, Guillermo L ópez-Vivanco, Manuel Cobo, José M. Sánchez, Jorge García-González, Javier Garde, Miguel Sampayo, Griselda Martrat, Andrea Malfettone, Niki Karachaliou, Miguel A. Molina-Vila, Rafael Rosel Tags: Original Research Source Type: research

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience
Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined. Herein, we present two cases of extrapulmonary tuberculosis (TB) that developed during pralsetinib therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Yong-Pyo Lee, Byeong-Ho Jeong, Yeonghee Eun, Cheol-In Kang, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun Tags: Original Research Source Type: research

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis
Immune checkpoint inhibitors (ICIs) have revolutionised clinical practice in oncology in the last years, leading to a survival benefit in several tumour types. To investigate whether these benefits are associated with improved quality of life, we conducted a systematic review and meta-analysis comparing patient-reported outcomes (PROs) between ICIs and standard chemotherapy (CT) in patients with advanced solid tumours. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Andrea Boutros, Marco Bruzzone, Enrica T. Tanda, Elena Croce, Luca Arecco, Federica Cecchi, Paolo Pronzato, Marcello Ceppi, Matteo Lambertini, Francesco Spagnolo Tags: Original Research Source Type: research

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation –positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation –positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 5, 2021 Category: Cancer & Oncology Authors: Yoshihiko Sakata, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Hiroshi Kobe, Hirotaka Matsumoto, Takashi Yokoi, Yuki Sato, Takeshi Uenami, Go Saito, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Tags: Original Research Source Type: research

Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
Immune checkpoint  inhibitors are widely used in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response rates to taxanes after progression on nivolumab in R/M HNSCC patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 4, 2021 Category: Cancer & Oncology Authors: Emeline Guiard, Florian Clatot, Caroline Even, Marion Perr éard, Cyril Abdeddaim, Alison Johnson, Elodie Vauléon, Audrey Rambeau Tags: Original Research Source Type: research

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
This study investigated the largest multicentre collection of NF1-mutated melanomas to date. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 4, 2021 Category: Cancer & Oncology Authors: Carl M. Thielmann, Eleftheria Chorti, Johanna Matull, Rajmohan Murali, Anne Zaremba, Georg Lodde, Philipp Jansen, Luisa Richter, Julia Kretz, Inga M öller, Antje Sucker, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alex Tags: Original Research Source Type: research

Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
To compare the prognosis and adverse effects of induction or adjuvant chemotherapy (IC or AC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in paediatric nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 4, 2021 Category: Cancer & Oncology Authors: Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai Tags: Original Research Source Type: research

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown. With the advent of poly(adenosine diphosphate –ribose) polymerase inhibitors (PARPi) in partially overlapping indications with cabazitaxel, we aimed to determine cabazitaxel activity in men with mCRPC according to their DDR status. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 2, 2021 Category: Cancer & Oncology Authors: Mihaela Aldea, Laurent Lam, Emeline Orillard, Casilda Llacer Perez, Mathilde Saint-Ghislain, Gwenaelle Gravis, Aude Fl échon, Guilhem Roubaud, Philippe Barthelemy, Francesco Ricci, Frank Priou, Zoe Neviere, Mathilde Beaufils, Brigitte Laguerre, Anne-Clai Tags: Original Research Source Type: research

Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis
Cancers of unknown primary (CUP) have traditionally been treated empirically, with a dismal prognosis. Compared with standard diagnostic tests, including CT and MRI, imaging with 18F-fluorodeoxyglucose (FDG) PET or PET/CT has shown the capacity to better identify the primary tumour site and detect additional sites of metastasis. However, its clinical impact is not well established. We performed a systematic review and meta-analysis of prior studies to assess the impact of FDG-PET or PET/CT on the management of patients with CUP. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 2, 2021 Category: Cancer & Oncology Authors: Sungmin Woo, Anton S. Becker, Richard K.G. Do, Heiko Sch öder, Hedvig Hricak, H. Alberto Vargas Tags: Original Research Source Type: research

Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
Increasing incidence rates of cutaneous melanoma (CM) observed during the last five decades in white populations are largely attributed to increased exposure to solar ultraviolet radiation (UVR), often expressed as population attributable fraction (PAF). Thus, many CMs could be prevented by reducing UVR exposure. The aim of this study was to estimate the PAF of CM attributable to UVR exposure and demographic changes in Denmark and Saarland/Germany for the period 1943 to 2036. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 2, 2021 Category: Cancer & Oncology Authors: Ulrike Keim, Sara Gandini, Teresa Amaral, Alexander Katalinic, Bernd Holleczek, Lukas Flatz, Ulrike Leiter, David Whiteman, Claus Garbe Tags: Original Research Source Type: research

The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy
Modern clinical cancer research increasingly relies on the visual communication of complex response and treatment sequencing data. Graphical representations used in oncology currently fail to provide adequate information on any prior treatment(s) responses, focussing on current treatment effects in isolation. We have developed a new graphical illustration, the ‘iceberg plot,’ to allow improved comparison of prior treatment response with current therapy.To demonstrate the potential clinical utility of this new graphical representation, we have performed an independent reanalysis of a clinical study triallin...
Source: European Journal of Cancer - November 1, 2021 Category: Cancer & Oncology Authors: Mark P. Lythgoe, Timoth ée Olivier, Vinay Prasad Tags: Current Perspective Source Type: research

Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C
Global statistics show that prostate cancer (PrCa) is the second most common non-cutaneous cancer diagnosed in men, and currently, it is the most commonly diagnosed cancer in Australian men [1]. While PrCa is a clinically complex, heterogeneous disease, it is one of the most heritable common cancers, with family history a strong predictor of susceptibility [2]. However, the identification of rare, high-risk germline variants for PrCa has lagged significantly behind other heritable cancers [3]. Massively parallel sequencing (MPS) applied to large families with a dense aggregation of disease, where genetic complexity is redu...
Source: European Journal of Cancer - November 1, 2021 Category: Cancer & Oncology Authors: James R. Marthick, Kelsie Raspin, Georgea R. Foley, Nicholas B. Blackburn, Annette Banks, Shaun Donovan, Roslyn C. Malley, Matthew A. Field, Janet L. Stanford, Elaine A. Ostrander, Liesel M. FitzGerald, Joanne L. Dickinson Tags: Letter to the Editor Source Type: research

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Nivolumab (an anti –programmed death-1 antibody) is an adjuvant standard of care for patients with high-risk resected melanoma, although a watch-and-wait strategy remains an option. In the absence of head-to-head evidence, an indirect treatment comparison (ITC) of adjuvant nivolumab versus placebo, the proxy for a w atch-and-wait strategy, was conducted in patients with high-risk resected melanoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 1, 2021 Category: Cancer & Oncology Authors: Jeffrey S. Weber, Paolo A. Ascierto, Mark R. Middleton, Delphine Hennicken, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati, Andriy Moshyk, Dirk Schadendorf Tags: Original Research Source Type: research